The company specializes in surgical implants made from bioresorbable polymers, which aim to prevent or reduce the formation of scar tissue after various surgical procedures. Their flagship product, REPEL-CV Bioresorbable Adhesion Barrier, is a film that is placed over the heart after cardiac surgery to minimize post-operative adhesions. SyntheMed obtained FDA clearance in 2009 to sell this product domestically. By leveraging their proprietary bioresorbable polymer technology, the company strives to address unmet therapeutic needs and enhance medical care for patients of all ages.